Sickle cell disease (SCD) is one of the most common genetic disorders in the United States and affects ϳ70 000 to 100 000 children and adults, predominantly of African and Hispanic descent. 1 SCD is a multisystem disease characterized by vascular injury caused by vaso-occlusion and hemolytic and infectious complications that contribute to high morbidity and mortality rates in this population. 2, 3 Many severe complications of SCD occur in childhood, including sepsis, stroke, acute chest syndrome, and painful episodes that require hospitalization. 2, 4 Universal newborn screening and advances in routine care, including penicillin prophylaxis 5 and immunization against serious bacterial infections, 6, 7 have significantly decreased mortality in young children with SCD. 8, 9 In addition, transcranial Doppler screening has been shown to identify children at higher risk of first-time stroke that can be treated prophylactically with chronic transfusion therapy. 10,11 However, research studies are lacking in key areas for children with SCD, including studies of disease-modifying treatments. For example, the Multicenter Study of Hydroxyurea was published in 1995 and a significant decrease was shown in painful episodes and acute chest syndrome in adults, 12 and a single-center study revealed decreased mortality with long-term use. 13 However, only 1 small randomized controlled trial (RCT) has been published on the use of hydroxyurea in children to date. 14 The purpose of this study was to review the quality of the literature for preventive interventions and treatment of complications for children with SCD to facilitate the use of evidence-based medicine in clinical practice and identify areas in need of additional research. In this study we have focused on level I evidence, because it typically helps define the standards of medical care, including for pediatric SCD.
METHODS Evidence Acquisition
We identified topics important to the care of children with SCD by using guidelines, 2,15 review articles, 3, 16 and clinical expertise. In addition, we specifically searched for screening, diagnostic, and treatment interventions used in routine SCD care to ensure their inclusion in this study. The 28 topics identified are listed in Table 1 . Individual topics were organized into 3 categories: (1) acute events; (2) chronic conditions; and (3) routine health care maintenance and disease-modifying treatments for SCD. Acute SCD-related events were defined as those that require urgent or emergent care. Chronic conditions included (1) SCDspecific complications that typically do not require immediate attention and persist for Ն 3 months (eg, avascular necrosis) and (2) chronic illnesses prevalent in the pediatric SCD population (eg, asthma). Finally, routine health care maintenance and disease-modifying treatments were defined as the comprehensive care needed for children with SCD. We searched for these topics in Ovid Medline for the time period of Janu- For each topic, we used several key words to identify relevant articles. We also added the term "sickle cell" to ensure that all of the articles captured for a topic were related to SCD and its specific genotypes (eg, sickle cell anemia, hemoglobin SC disease). We limited each search to "children 0 -18 years" and "human" (Appendix 1). In addition to abstracts identified electronically, we performed an ad hoc search of bibliographies of articles selected for this review.
Study Selection
Each abstract was independently reviewed by 2 authors (Drs Kavanagh, Wang, and Sprinz). Abstracts were selected for full-article review if they pertained to the key topics identified, used experimental (eg, RCT) or quasiexperimental (eg, cohort studies with comparison groups) research methods, and enrolled children in the study. If the research methods were unclear in the abstract, the article was reviewed in detail. Studies were excluded if they enrolled adults only, were in vitro or animal studies, gene or genome-wide association studies, non-English-language abstracts or articles, commentaries or editorials, or case reports. We also excluded longitudinal cohort studies that presented outcomes aggregated over 1 or more decades without description of the care processes. Although these studies could provide important information on the historical natural history of SCD, they might not reflect outcomes that could be achieved under current standards of care.
Data Extraction
Articles selected from the review of abstracts were retrieved for full article evaluation. Data were abstracted by each reviewer using a common form.
The abstraction form included fields for the number of participants, population of interest, intervention(s) studied, and study design. Differences in coding were reconciled by the pair of reviewers (Drs Kavanagh, Wang, and Sprinz) in consultation with the third reviewer as needed. All references and abstracted data were maintained in Microsoft Excel 2003 (Redmond, WA).
Quality of the Literature
The hierarchy of research design was assigned following the US Preventive Services Task Force ratings. 17 RCTs and meta-analyses were categorized as level I evidence. Level II evidence included well designed controlled trials without randomization, cohort and case-control studies, multiple time series analyses, and results from uncontrolled experiments. Level III evidence was defined as studies reflecting the opinions of respected authorities on the basis of clinical experience, descriptive studies or case reports, and reports of expert committees.
RESULTS
We identified 3188 abstracts for screening (Fig 1) . Of these, 2867 abstracts were eliminated because of duplicate references, topic, study design, population, non-English-language abstract or article, outdated reviews or unable to be retrieved. There were 321 (10% of abstracts screened) articles selected for full review (Appendix 2), of which 26 were rated as level I evidence (Table 1) . We identified 25 RCTs and 1 meta-analysis from which we extracted summary data. Eighteen of the 28 topics selected for this literature review did not have level I evidence published during this 15-year period. Of the 321 articles selected for full review, 111 and 184 articles were categorized as level II and level III evidence, respectively (Table 1) .
Acute Events
Twelve RCTs were identified for 2 topics: acute chest syndrome (ACS) and pain episodes (Table 2) . We did not find any level I evidence for the acute management of aplastic anemia, fever/sepsis, osteomyelitis, priapism, splenic sequestration, or stroke in children with SCD for the 15-year period reviewed.
Two RCTs have been performed for ACS. In a pilot RCT, elevated serum phospholipase A2 seemed to identify those at risk of ACS, which could be prevented by a single blood transfusion. 18 In addition, treatment with dexamethasone limited the severity of ACS in children, although it was associated with rehospitalization for severe pain within 72 hours of discharge. 19 The treatment and prevention of SCDrelated pain accounted for nearly 40% of the level I studies identified. Ten RCTs were identified for the management of SCD-related pain in children; 7 examined treatment regimens and 3 studied pain prophylaxis. Tinzaparin decreased the number of severe pain days and hospital days but was associated with minor bleeding events in 1.5% of patients. 20 In a pilot RCT it was found that nitric oxide was also a potentially useful as a treatment for acute pain. 21 However, poloxamer 188 had little 22 to no 23 effect on the duration of pain in intent-to-treat analyses, and ketorolac 24 proved ineffective as an adjunct to opioid treatment for severe pain requiring hospitalization. Sustained-release oral morphine proved as effective as the parenteral formulation in the inpatient setting 25 ; however, it was associated with an increased incidence of ACS in posthoc analyses. 26 In resource-poor settings, the nonsteroid anti-inflammatory drug piroxicam was superior to aspirin for SCD-related pain. 27 For pain prophylaxis, massage therapy was shown to decrease average pain scores among children with SCD, but increased anxiety among the parents administering it and had no effect on health care use. 28 Piracetam was not found effective in a Brazilian RCT 29 ; however, the Nigerian herbal remedy Niprisan did decrease the number of severe pain episodes. 30
Chronic Conditions
For SCD-related leg ulcers, a pilot RCT compared oral propionyl-L-carnitine to placebo in adolescents and adults, but showed no benefit as an adjunct to usual care (Table 2) . 31 Level I evidence was not available for the management or prevention of asthma, avascular necrosis, gall bladder disease, hepatic dysfunction, nephropathy, pulmonary hypertension, retinopathy, and silent infarcts/neuropsychological testing.
Routine Health Care Maintenance and Disease-Modifying Treatments
Our review found 1 meta-analysis and 12 RCTs for 7 of the 11 topics included in this category (Table 3) . However, no level I evidence was identified for cardiac care, folate supplementation, genetic counseling, or hematopoietic stem cell transplant. Hydroxyurea is currently used to treat individuals with severe manifestations of SCD. Only 1 small RCT has been published on its use in children with SCD to date, which showed a significant reduction in the number of hospitalizations and length of stay. 14 Results from the Stroke With Transfusions Changing to Hydroxyurea (SWiTCH) study 45 and Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG), [46] [47] [48] [49] in which the efficacy of hydroxyurea was examined in secondary stroke prevention and prevention of end-organ damage in infants with SCD, respectively, were not published at the time of this review. However, it is suggested in preliminary data from Infant HUGS that hydroxyurea use decreased the frequency of pain episodes and ACS in young children. 46 In addition, RCTs have not been conducted on different conditioning regimens or other aspects of management of hematopoietic stem cell transplantation in this population.
DISCUSSION
To our knowledge, this is the first comprehensive review of the literature for the care provided to children with SCD. On the basis of the results of this study, Ͻ1% of studies for children with SCD published from January 1995 to April 2010 represent level I evidence. In addition, Ͼ60% (18 of 28) of the topics selected for this review did not have any RCTs or meta-analyses supporting treatment or prevention strategies for pediatric SCD. These findings are consistent with our review of the Cochrane Library of Systematic Reviews, in which it was concluded that in 14 of the 29 reviews on pediatric SCDrelated topics no high-quality studies currently exist. The lack of RCTs performed in children with SCD is not unique to this population. Although we did not search the adult SCD literature to make a direct comparison, it was found in previous reports on other topics that significantly fewer high-quality studies have been published for children compared with adults in the both the generalist 50 and specialist 51 journals.
The area most in need of additional investigation is acute events associated with SCD because many are associated with significant morbidity and mortality. We did not find any high-quality studies for 75% of the acute events listed, including the management of splenic sequestration and treatment of overt strokes. In addition, the level I evidence found for SCD-related pain focused primarily on the management of severe pain requiring emergency department or inpatient care. However, most pain episodes are managed at home, 52 and no high-quality studies have been conducted in this setting to date. 53 In only 3 of the 26 studies included in this review was the effect of SCD measured on a child's academic achievement, parental stress level, or the quality of life of either the child or their parents. 28,29,32 However, many SCDrelated complications, particularly pain episodes, might last for days or weeks after the health care encounter. 2, 54 These outcomes are important measures to capture for children, especially those with chronic illness such as SCD, because their disease can negatively impact both their educational attainment and their family life. [55] [56] [57] In this review we focused on RCTs and meta-analyses conducted on children with SCD. However, there are circumstances when conducting a RCT might not be feasible. For example, it is impractical to use a RCT to study conditioning regimens for hematopoietic stem cell transplant at present because only a small number of children with severe SCD-related complications currently undergo this procedure. Research methodologies such as comparative effectiveness research and long-term observation studies can provide valuable information for these interventions.
There are several potential limitations to this study. First, we might have missed some studies by using our defined search strategies, including studies that enrolled both children and adults. However, we believe that our use of a broad approach using a combination of electronic search terms and hand-searches of bibliographies minimized the omission of important studies. In addition, more than onethird of studies selected for full review (90/321 articles) included both pediatric and adult subjects. Second, we limited our review to the English-language literature, which possibly eliminated important studies conducted abroad. However, by reviewing the bibliography of the articles reviewed for this study and those cited in National Institutes of Health guidelines for the management of SCD, 2 we believe that we captured the important articles on this subject. Third, we used Ovid Medline to conduct our searches, which largely focuses on the medical literature produced in North America. Therefore, we might have missed European and other international studies that would have been identified had another database been used. However, we captured a large number of European, South
American, and African studies in this review, whose bibliographies were used to supplement our electronic searches. Fourth, we conducted our literature searches using a list of predefined topics for pediatric SCD. Although we might have missed highquality studies in areas not considered in this review, we believe this effort had an appropriately broad scope to comment on the evidence for the care currently provided to children with SCD. Finally, we limited our study to the 15-year period that ended April 2010 to focus on the recent advances in pediatric SCD. Although studies done before 1995 contributed significantly to the knowledge base, a review of the 15-year period (1980 -1994) before our study revealed 7 RCTs had been conducted during this time. 5,58-63 Except for folate supplementation, these studies informed subsequent trials which are included in this report, which have helped define the current standard of care for children with SCD. 
CONCLUSIONS

